1090 Horsham Road
About Teva Pharmaceuticals
Teva Pharmaceutical Industries Ltd. develops, produces and markets ethical drugs, generic drugs, and fine chemicals for the pharmaceutical industry and disposable products for hospitals and home care services.
1539 articles with Teva Pharmaceuticals
Over a 12-week course of treatment, Teva said fremanezumab provided patients with statistically significant reductions in monthly average number of migraine days. The results of the study were published in Lancet.
Fremanezumab Data in The Lancet Demonstrate Clinically Meaningful Reduction in Monthly Migraine Days Versus Placebo for Patients with Difficult-To-Treat Migraine
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that results from the Phase IIIb FOCUS study, which examined fremanezumab versus placebo in adult migraine patients who previously experienced inadequate responses to two to four classes of preventive treatments, were published online ahead of print in The Lancet.
SHAREHOLDER ALERT - Teva Pharmaceutical Industries Ltd. (TEVA) - Bronstein, Gewirtz & Grossman, LLC Alerts Stockholders of Class Action and Lead Plaintiff Deadline: August 20, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Teva Pharmaceutical Industries Ltd. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Teva American Depositary Shares between August 4, 2017 and May 10, 2019, inclusive.
Teva Announces Availability of a Generic Equivalent of EpiPen Jr® (epinephrine injection, USP) Auto-Injector, 0.15 mg in the United States
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, 0.15 mg, in the U.S.
8/9/2019Biopharma companies strengthen their senior leadership teams and boards of directors.
Teva Pharmaceuticals, Endo Pharmaceuticals and Taikoku Pharma entered into settlement agreements with the State of California for a total of almost $70 million. The settlements were over non-competitive, inter-company deals that prevented cheaper drugs from entering the market.
CORRECTING and REPLACING Alcoholic Hepatitis Treatment Market Worth USD 570 Million, at 6% CAGR during 2019-2023 | Technavio
According to Technavio Research Report "Alcoholic Hepatitis Treatment Market by type (corticosteroids, xanthine derivatives, and others), and geographic regions (North America, Europe, Asia, and ROW) is witnessed to grow by USD 570 million, at a CAGR of 6% from 2019 to 2023”.
Teva Presents Positive Results Showing Improvement in Disability and Quality of Life from the Phase IIIb FOCUS study of Fremanezumab in Adults with Migraine
These results include reduction in monthly average migraine days; reduction in migraine related symptoms; and improvements in depression status; work productivity and activity impairment.
TEVA PHARMACEUTICAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Teva Pharmaceutical Industries Ltd
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 20, 2019 to file lead plaintiff applications in a securities class action lawsuit against Teva Pharmaceutical Industries Limited (NYSE: TEVA), if they purchased the Company's American Depository Shares ("ADS") between August 4, 2017 and May 10, 2019, inclusive (the "Class Period").
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Tracleer®1 (bosentan) tablets, 62.5 mg and 125 mg, in the U.S.
Teva to present new fremanezumab FOCUS Clinical Study Data for the first time at the 13th European Headache Federation Congress
Teva Pharmaceutical Industries Ltd. announced that data from the Phase IIIb FOCUS study, which evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients who previously experienced inadequate response to two to four classes of migraine preventive treatments, will be available at the 13th European Headache Federation Congress.
Teva Announces Launch of a Generic Version of Ranexa® (ranolazine) Extended-Release Tablets in the United States
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Ranexa®1 (ranolazine) Extended-Release Tablets, 500 mg and 1000 mg, in the U.S.
TEVA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Teva Pharmaceutical Industries Limited To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Teva Pharmaceuticals Industries Limited.
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
5/13/2019Gilead's Truvada is expected to lose patent protection in 2021, but a recent court decision in Europe could change that.
Teva Announces the Launch of a Generic Version of Delzicol® (mesalamine) Delayed-Release Capsules in the United States
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the launch of a generic version of Delzicol®1 (mesalamine) delayed-release capsules, 400 mg, in the U.S.
Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of Tarceva®1 tablets, 100 and 150 mg, in the U.S.
Teva to Present New Long-Term Data on Efficacy and Safety of Fremanezumab at 2019 American Academy of Neurology Annual Meeting
Findings describe the efficacy and safety results of clinical trials of fremanezumab through 12 months of treatment in patients with chronic and episodic migraine
Spend base reduction of $2.5 billion since initiation of the restructuring plan in 2018; on-track to achieve $3.0 billion by the end of 2019
Teva Pharmaceutical Industries Ltd., announced the launch of a generic version of Letairis®1 Tablets, 5 mg and 10 mg, in the U.S.